13F Holdings
中文EN

CRBU Caribou Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1619856 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.6%
TTM net income YoY34.8%
TTM EPS YoY39.4%
Revenue 3-yr CAGR-35.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,140.6%
Net margin-1,085.0%
FCF margin-984.6%
EBITDA margin-1,113.6%

Returns

ROE-93.8%
ROA-64.4%
ROIC (approx.)-93.9%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets37.7%
Debt / equity0.00x
Current ratio4.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue-1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$11.16M$9.99M$34.48M$13.85M$9.60M
R&D expense$109.44M$130.15M$112.08M$82.23M$52.26M
SG&A expense$37.91M$46.46M$38.46M$38.02M$24.32M
Operating income-$148.34M-$166.62M-$116.06M-$106.40M-$66.98M
Interest expense————$8,000
Pretax income-$148.68M-$149.11M-$101.88M-$99.35M-$66.60M
Income tax-$550,000-$9,000$193,000$70,000$321,000
Net income-$148.12M-$149.10M-$102.07M-$99.42M-$66.92M
EBITDA-$144.70M-$162.69M-$112.53M-$104.78M-$66.00M
EPS (basic)-1.59-1.65-1.38-1.64-2.11
EPS (diluted)-1.59-1.65-1.38-1.64-2.11
Weighted avg. shares (diluted)93.39M90.32M73.81M60.80M31.66M
Balance sheet
Cash & equivalents$12.36M$16.34M$51.21M$58.38M$240.47M
Short-term investments$126.98M$193.24M$277.67M$189.32M$135.41M
Receivables$69,000$265,000$148,000$202,000$1.15M
Current assets$145.23M$219.38M$338.84M$260.25M$391.19M
PP&E, net$6.76M$19.28M$18.27M$10.68M$4.89M
Total assets$175.37M$313.31M$432.21M$373.76M$442.36M
Current liabilities$25.41M$30.65M$28.30M$28.13M$25.83M
Total liabilities$53.19M$60.36M$63.81M$72.89M$54.53M
Shareholders' equity$122.17M$252.95M$368.40M$300.87M$387.82M
Shares outstanding95.14M92.38M88.45M61.03M60.26M
Cash flow statement
Operating cash flow-$110.99M-$138.20M-$93.29M-$90.97M-$32.52M
Capital expenditure$1.36M$4.88M$11.61M$6.45M$2.12M
Free cash flow-$112.35M-$143.08M-$104.90M-$97.42M-$34.64M
Investing cash flow$102.24M$86.61M-$68.18M-$93.25M-$176.40M
Financing cash flow$4.82M$16.72M$154.30M$2.13M$433.43M
Depreciation & amortization$3.65M$3.93M$3.52M$1.62M$984,000
Stock-based compensation$12.68M$16.71M$13.75M$11.72M$3.45M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.